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Abstract
Our research on pathogenesis of disseminated candidiasis led to the discovery that antibodies specific for Candida albicans
cell surface b-1, 2–mannotriose [b-(Man)3] protect mice. A 14 mer peptide Fba, which derived from the N-terminal portion of
the C. albicans cytosolic/cell surface protein fructose-bisphosphate aldolase, was used as the glycan carrier and resulted in a
novel synthetic glycopeptide vaccine b-(Man)3-Fba. By a dendritic cell-based immunization approach, this conjugate
induced protective antibody responses against both the glycan and peptide parts of the vaccine. In this report, we modified
the b-(Man)3-Fba conjugate by coupling it to tetanus toxoid (TT) in order to improve immunogenicity and allow for use of
an adjuvant suitable for human use. By new immunization procedures entirely compatible with human use, the modified b-
(Man)3-Fba-TT was administered either alone or as a mixture made with alum or monophosphoryl lipid A (MPL) adjuvants
and given to mice by a subcutaneous (s.c.) route. Mice vaccinated with or, surprisingly, without adjuvant responded well by
making robust antibody responses. The immunized groups showed a high degree of protection against a lethal challenge
with C. albicans as evidenced by increased survival times and reduced kidney fungal burden as compared to control groups
that received only adjuvant or DPBS buffer prior to challenge. To confirm that induced antibodies were protective, sera from
mice immunized against the b-(Man)3-Fba-TT conjugate transferred protection against disseminated candidiasis to naı ¨ve
mice, whereas C. albicans-absorbed immune sera did not. Similar antibody responses and protection induced by the b-
(Man)3-Fba-TT vaccine was observed in inbred BALB/c and outbred Swiss Webster mice. We conclude that addition of TT to
the glycopeptide conjugate results in a self-adjuvanting vaccine that promotes robust antibody responses without the need
for additional adjuvant, which is novel and represents a major step forward in vaccine design against disseminated
candidiasis.
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Introduction
Hematogenously disseminated candidiasis in humans has
become the third or fourth leading cause of hospital-acquired
blood stream infections and despite antifungal therapy at least
40% of affected individuals will die of this disease [1,2]. It’s
estimated that 60–70,000 cases of disseminated candidiasis occur
per year in the US alone, and associated health care costs are $2–4
billion/year [3]. The limited number and toxicity of antifungal
agents, and, most importantly, the poor outcome of almost half of
the number of candidemia patients treated with appropriate
antifungal therapy, militates in favor of disease prevention,
possibly through active and passive immunization strategies [4–
6]. Strong evidence has accumulated in the last decade that
antibodies specific for certain cell surface epitopes of fungi may be
beneficial for the fungal-infected host [7–13]. In addition, if a
vaccine maintains a long-lived protective antibody titer, we argue
that this form of disease prevention could be induced and protect
individuals who will enter into a possible transient immunocom-
promised state, such as those patients who will have elective
abdominal or other surgical procedures that will place them at risk
of developing candidiasis.
Depending on the clinical setting there is a wide spectrum of
Candida species that may cause disseminated candidiasis, but C.
albicans continues to be prevalent overall and this species is the
most virulent in experimental animals [14,15]. Antibodies have
long been considered irrelevant in host defense against invasive
candidiasis, but over the last two decades a number of antibodies
or their engineered derivatives directed against C. albicans cell-wall
polysaccharides and glycopeptides, as well as against some protein
or peptide epitopes, have been shown to confer protection
[6,12,16,17]. We previously demonstrated that complement-fixing
antibodies that recognize C. albicans cell surface b-1,2-linked
mannotriose [b-(Man)3] protect mice against candidiasis [18,19].
Our finding that a C. albicans cell surface peptide Fba, derived from
the N-terminal portion of C. albicans cell wall protein fructose-
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the glycan has resulted in a novel fully synthetic glycopeptide
vaccine [7]. Following immunizations of mice, protection was
afforded by antibodies specific for the b-(Man)3 and the Fba
epitopes that comprised the vaccine [7]. The antibody dependency
of protection was evident by protection transferred to naı ¨ve mice
by immune serum, but not by serum pre-absorbed with C. albicans.
These results enabled elucidation of an efficacious vaccine, but the
immunization protocol utilized dendritic cells and complete
Freund adjuvant (DC/CFA), which are cost prohibitive and
incompatible for human use, respectively. In this report, we have
investigated alternative vaccine presentation strategies to test our
hypothesis that an approved human adjuvant can be substituted
for the DC/CFA approach provided that the vaccine conjugate
can be appropriately modified to improve immunogenicity.
Prior to vaccine modification, we expanded our observation on
efficacy of the b-(Man)3-Fba vaccine in additional mouse strains
and against challenge with an additional C. albicans strain, and
tested whether the vaccine could be administered with alum or
monnophosphoryl lipid A (MPL) adjuvants in place of DC/CFA.
In subsequent experiments, the vaccine modification was the
covalent coupling of tetanus toxoid (TT) to the b-(Man)3-Fba. The
b-(Man)3-Fba-TT conjugate was administered alone or as a
mixture made with alum or MPL. The best protection results
occurred in animals immunized against the b-(Man)3-Fba-TT
conjugate vaccine with, or, surprisingly, without additional
adjuvant. This self-adjuvanting b- (Man)3-Fba-TT conjugate
vaccine, administered without any additional adjuvant, induced
robust antibody responses and antibody-mediated protection in
mice.
Results
Protective efficacy of b-(Man)3-Fba conjugate vaccine in a
different mouse strain and against an additional C.
albicans strain
As we described, the b-(Man)3-Fba conjugate vaccine induced
strong antibody responses and protective immunity in BALB/c
mice [7] that express the H-2
d MHC haplotype and have a Th-2
immunologic bias [20,21]. C57BL/6 mice express an H-2
b MHC
haplotype, are more prone to Th1 responses and supposedly more
resistant to disseminated candidiasis than are BALB/c mice [21–
23]. We derived dendritic cells in vitro as described before [7] and
used the same immunization DC/CFA-strategy on the C57BL/6
mice as was used in our work on BALB/c mice [7], which
included a priming dose followed by two boosters; the last booster
consisted of the vaccine emulsified in CFA. C57BL/6 mice
responded to the vaccine by making specific antibody against each
of the two vaccine epitopes, i.e., the b-(Man)3 and the Fba peptide
(data not shown). Following the first booster, an isotype switch
from IgM to IgG occurred in response to each epitope. The
immunized C57BL/6 mice showed 80% survival throughout the
120 days post challenge and survived significantly longer
(p,0.001) as compared to the control groups of mice given DPBS
buffer, DC or DC+CFA (Figure S1A). The survival data were
consistent with the trend of colony forming units (CFU) in kidney
homogenates. That is, immunized C57BL/6 mice had greatly
reduced or non-detectable kidney CFU as compared to controls
that were sacrificed when they became moribund following i.v.
challenge with the fungus (Figure S1B). Indeed, the protection in
C57BL/6 mice was similar to that which we observed for BALB/c
mice [7].
To answer whether antibody responses were responsible for the
protection, antisera were collected from separate groups of
immunized mice and transferred i.p. to naı ¨ve mice 4 h before
i.v. challenge with a lethal dose of C. albicans strain 3153A. Control
groups were given either immune sera pre-absorbed with live C.
albicans yeast cells or DPBS buffer prior to the challenge. The
immune serum donors, which were immunized with b-(Man)3-Fba
by the DC/CFA method, were used as positive controls for
protection. After challenge, immunized mice and mice treated
with the antiserum had prolonged survival times as compared to
the two control groups (p,0.05) (Figure S1C), and as expected,
mice that received the antiserum had significantly reduced fungal
counts in their kidneys (p,0.05) (Figure S1D). These data provide
strong evidence that antibodies are responsible, at least in part, for
the vaccine-induced protection against a lethal challenge with the
fungus in C57BL/6 mice.
C. albicans strain 3153A was used in our previous studies
[7,17,19]. To test if DC/CFA vaccination with the b-(Man)3-Fba
protects C57BL/6 mice challenged with another C. albicans strain,
we challenged immunized mice with C. albicans strain SC5314, a
clinical isolate commonly used in research. As a positive control, a
group of immunized mice was challenged with strain 3153A.
Similar protection patterns were observed in both groups of mice
regardless of the challenge strain (Figure S1E). In addition to
prolonged survival times, immunized groups had reduced or non-
detectable CFUs in their kidneys as compared to non-immune mice
(data not shown). These results are similar to those we observed
from BALB/c mice challenged with the 3153A strain [7,19]. The
above experiments are important as they show that vaccine-induced
antibody protection is not animal or fungal-strain dependent.
Immunization with b-(Man)3-Fba combined with alum or
MPL induced modest antibody responses and slight
protection
Although the DC/CFA -based immunization approach was
successful in mice for protection against disseminated candidiasis,
the use of DC and complete Freund adjuvant are inappropriate for
human use. To test new adjuvants suitable for human use, the b-
(Man)3-Fba conjugate was administered as a mixture with either
alum or MPL adjuvants. After the first booster, immune sera from
vaccinated mice showed modest antibody responses (OD values of
a 1/100 serum dilution: 0.7–0.9) to the Fba peptide (Figure 1A),
and relatively weak antibody responses (OD values of a 1/100
serum dilution: 0.45–0.55) to the b-(Man)3 epitope (Figure 1B).
Following the second booster immunization, an isotype switch
from IgM to IgG of either b-(Man)3 or Fba specific antibodies was
low to negligible in immune sera (data not shown, results
summarized in table 1), which suggested that an immune memory
response had not occurred. In addition, the b-(Man)3-Fba
vaccinated groups had insignificantly longer survival times as
compared to the two non-immunized control groups after
challenge with a lethal dose of C. albicans cells (p=0.77) (Figure 1C).
In an attempt to increase the antibody and protective responses,
the dose of b-(Man)3-Fba conjugate was increased from 2.5 mgt o
10 mg in the b-(Man)3-Fba+alum formulation. Nonetheless, the
levels of anti-Fba peptide (Figure 2A) and anti-b-(Man)3 (Figure 2B)
were markedly less than antibody levels (OD values of a 1/100
serum dilution: 1.7–1.9) in sera from control animals immunized
with the b-(Man)3-Fba+DC/CFA. Likewise, when titers were
assessed by end-point dilution, the immune sera from the positive
control group showed significantly greater antibody responses for
both epitopes (Table 2 & 3). Interestingly, even though the
Vaccination against Disseminated Candidiasis
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35106antibody titers against both epitopes in response to the 10
microgram dosage was greater than the response to the 2.5 mg
dose, disease protection was not observed to the extent of
protection induced by the DC/CFA immunization approach
(Figure 2C). In summary, the greatest antibody responses occurred
in mice that received the b-(Man)3-Fba+DC/CFA, the animals of
which also showed evidence of an IgM-IgG shift (Table 2 & 3) and
the highest degree of protection [7].
Addition of tetanus toxoid (TT) to the vaccine, b-(Man)3-
Fba-TT, markedly enhanced antibody responses to both
epitopes in the presence of alum or MPL
In an attempt to improve immunogenicity of the glycopeptide
vaccine in the presence of adjuvant suitable for human use, we
modified the b-(Man)3-Fba conjugate by coupling it to tetanus
toxoid designated as b-(Man)3-Fba-TT. In a preliminary exper-
iment we also tested the Fba peptide as a Fba-TT conjugate. Both
conjugates were administered as mixtures with alum or MPL.
Negative control groups included adjuvant only and DPBS buffer
only. After the first booster, mice immunized with b-(Man)3-Fba-
TT prepared in either alum or MPL produced robust antibody
responses against both the Fba peptide (Figure 3A) and the b-
(Man)3 epitopes (Figure 3B), titers of which were 100 fold greater
than that of sera from groups that received Fba-TT (p,0.001)
(Table 2 & 3), the latter of which responded about the same as
animals that received Fba in alum without TT (Figure 3A). After
Figure 1. b-(Man)3-Fba administered along with either alum or MPL adjuvants induced modest antibody responses and slight
protection against disseminated candidiasis. The b-(Man)3-Fba conjugate was administered as a mixture with either alum or MPL adjuvants in
BALB/c mice. Serum samples were collected 14 days after immunization, diluted 1:100 and tested by ELISA on plates coated with synthetic b-(Man)3
or Fba-MAP. After the first booster immunization, immune sera from vaccinated mice showed modest antibody responses to Fba peptide (A) and
relatively weak antibody responses to b-(Man)3 epitope (B) (C) The survival was also slightly extended in mice that received b-(Man)3-Fba in MPL and
slight protection was observed when alum was used as the adjuvant as compared to DPBS or adjuvant unimmunized controls.
doi:10.1371/journal.pone.0035106.g001
Table 1. Antibody isotype distribution of responses to Fba
and b-(Man)3.
Sera induced by vaccines anti b-(Man)3 anti Fba-peptide
b-(Man)3-Fba-TT with MPL IgM;IgG1;IgG2a;IgG2b IgM;IgG1
b-(Man)3-Fba-TT with alum IgM;IgG1;IgG2a IgM;IgG1;IgG2a
b-(Man)3-Fba-TT IgM;IgG1;IgG2a IgM;IgG1;IgG2a
b-(Man)3-Fba IgM IgM
b-(Man)3-Fba with alum IgM IgM
b-(Man)3-Fba with MPL IgM IgM
b-(Man)3-Fba+DC+CFA IgM;IgG1 IgM;IgG1
doi:10.1371/journal.pone.0035106.t001
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were detected in the sera of mice immunized with b-(Man)3-Fba-
TT with added alum or MPL adjuvants (Table 1), whereas very
low levels of anti-Fba IgM and IgG antibodies were detected in the
sera of mice that received Fba or Fba-TT in adjuvant. No
antibody against the epitopes was detectable in any of the negative
(i.e., adjuvant or DPBS mice) control sera (data not shown).
The b-(Man)3-Fba-TT conjugate vaccine induced high
antibody responses and protection even in the absence
of adjuvant
To determine whether the immunogenicity of b-(Man)3-Fba-
TT vaccine was dependent on additional adjuvant, b-(Man)3-Fba-
TT was administered alone and the response of these mice was
compared to those that received the vaccine as a mixture made
Figure 2. Comparison of DC/CFA and alum as adjuvants for induction of immune resopnses to the b-(Man)3-Fba conjugate vaccine.
Serum samples were collected 14 days after immunization, diluted 1:100 and tested by ELISA on plates coated with either synthetic Fba-MAP or b-
(Man)3. Immune sera from mice immunized with the b-(Man)3-Fba DC/CFA showed greater antibody titers to both the Fba peptide (A) and the b-
(Man)3 epitopes (B) than sera from groups that received b-(Man)3-Fba in alum. (C) A high degree of protection was induced by the b-(Man)3-Fba
pulsed DCs, and slight protection was observed when alum was used as the adjuvant as compared to DPBS, DC+CFA or alum adjuvant unimmunized
controls.
doi:10.1371/journal.pone.0035106.g002
Table 2. ELISA titers against microtiter wells coated with synthetic b-(Man)3 epitope.
Sera induced by vaccines anti b-(Man)3 ELISA titers* (*n=5 mice per group)
b-(Man)3-Fba-TT with MPL I2,800 25,600 25,600 25,600 25,600
b-(Man)3-Fba-TT with alum I2,800 12,800 25,600 25,600 25,600
b-(Man)3-Fba-TT I2,800 25,600 25,600 12,800 25,600
b-(Man)3-Fba with alum I,600 400 400 400 800
b-(Man)3-Fba with MPL I,600 800 800 400 400
b-(Man)3-Fba 400 400 400 400 400
b-(Man)3-Fba+DC+CFA 51,200 25,600 25,600 25,600 51,200
doi:10.1371/journal.pone.0035106.t002
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prepared in either adjuvant responded as expected by making
robust antibody responses. Surprisingly, mice that received the b-
(Man)3-Fba-TT without adjuvant responded only slightly, but not
significantly, less than those that received the vaccine plus
adjuvant (Figure 4A+4B). Importantly, all three groups of mice,
vaccinated with b-(Man)3-Fba-TT conjugate vaccine with or
without additional adjuvant, showed a high degree of protection
against a lethal challenge with C. albicans (Figure 4C). The induced
protective immunity was evidenced by significantly prolonged
survival times (p,0.005)and reduced kidney fungal burden
(p,0.001) as compared to control groups that received only
adjuvants or DPBS buffer prior to challenge (Figure 4D). These
results showed the self-adjuvanticity power of the b-(Man)3-Fba-
TT vaccine.
Anti-b-(Man)3-Fba-TT immune sera induced by non-DC/
CFA-based immunization approaches provided passive
protection
In previous work we showed by passive transfer experiments
that antibodies induced by the DC/CFA-based immunization
approach are responsible for protection against disseminated
candidiasis. To confirm that vaccine-induced antibodies are
protective regardless of the use of dendritic cells, immune sera
were collected and pooled from b-(Man)3-Fba-TT (with or without
alum or MPL adjuvants) immunized mice and transferred i.p. to
naı ¨ve mice 4 h before i.v. challenge with a lethal dose of C. albicans.
Control groups were given either immune serum pre-absorbed
with live C. albicans yeast cells or DPBS buffer prior to the
challenge. We tested for antibodies against the b-(Man)3 and Fba
eptiopes before and after absorption with yeast cells. Immune
serum donors, which were immunized with b-(Man)3-Fba-TT
conjugate vaccine, were used as a positive control for protection.
After challenge, immunized positive control mice and mice treated
with the antiserum had prolonged survival times as compared to
the two negative control groups (p,0.01) (Figure 5A), confirming
that induced antibodies were protective and that their induction
was not dependent on the use of dendritic cells or CFA during the
immunizations. Consistently, mice that received the antiserum had
significantly fewer fungal counts in their kidneys compared with
the infectious burden in mice that were given DPBS or pre-
absorbed serum prior to challenge (p,0.001) (Figure 5B).
Table 3. ELISA titers against microtiter wells coated with synthetic Fba peptide.
Sera from vaccine groups anti- Fba peptide ELISA titers* (*n=5 mice per group)
b-(Man)3-Fba-TT with alum 51,200 25,600 51,200 51,200 25,600
b-(Man)3-Fba-TT with MPL 51,200 25,600 25,600 25,600 25,600
b-(Man)3-Fba-TT 51,200 25,600 25,600 51,200 25,600
Fba-TT with alum 400 400 200 N/A N/A
Fba-TT with MPL 400 400 200 N/A N/A
b-(Man)3-Fba with alum 800 800 1600 800 800
b-(Man)3-Fba with MPL 800 800 800 400 800
b-(Man)3-Fba 400 400 400 400 400
b-(Man)3-Fba+DC+CFA 51,200 102,400 51,200 51,200 102,400
doi:10.1371/journal.pone.0035106.t003
Figure 3. Vaccination with b-(Man)3-Fba-TT in either alum or MPL markedly increased both b-(Man)3 and Fba peptide-specific
antibody titers in sensitized mice as compared to controls. Serum samples were collected 14 days after immunization, diluted 1:100 and
tested by ELISA on plates coated with cell wall mannan or peptide. MAbs B6.1 and E2-9 that are specific for b-(Man)3 and Fba, respectively, were used
as positive controls. Mice immunized with b-(Man)3-Fba-TT prepared in either alum or MPL induced robust antibody responses against both the Fba
peptide (A) and the b-(Man)3 (B) epitopes. However, mice that received either Fba or Fba-TT in either adjuvant produced weak anti-Fba responses.
doi:10.1371/journal.pone.0035106.g003
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for antibodies specific for either fungal epitope in the
vaccine conjugate
We compared antibody isotype responses to both the glycan and
peptide epitopes induced by the b-(Man)3-Fba conjugate when the
DC/CFA-based immunization approach was employed to that
produced by the b-(Man)3-Fba-TT modified conjugate adminis-
tered with alum or MPL or when given alone (Table 1). b-(Man)3-
Fba+DC/CFA and b-(Man)3-Fba-TT immunized mice produced
antibodies to both the b-(Man)3 epitope and Fba peptide, and the
isotype analysis revealed an abundance of IgM and IgG subclasses
in the immune sera against both epitopes, which is consistent with
the induction of a T cell-dependent memory immune response.
The isotype distribution of antibodies specific for the fungal
epitopes differed depending on the adjuvant system (Table 1).
Whereas IgM and IgG1 responses to b-(Man)3 were induced
regardless of the presence of adjuvant, an IgG2a response to the
glycan epitope was induced by b-(Man)3-Fba-TT with or without
the use of alum or MPL, but IgG1 was the only subclass detectable
in mice immunized by the DC/CFA approach. Only mice
immunized with the b-(Man)3-Fba-TT mixed with MPL produced
an IgG2b response to the glycan epitope. Antibody IgM and IgG1
isotype responses to the Fba peptide were similar for mice
immunized with the b-(Man)3-Fba regardless of the adjuvant
system, however, IgG2a specific for the peptide epitope was
induced only by b-(Man)3-Fba-TT with alum or when no adjuvant
was used. No IgG2a isotype was detected against the peptide when
MPL was the test adjuvant. The level of protection observed
against disseminated candidiasis was similar in mice immunized
with the glycan-peptide conjugate in the DC/CFA approach, or in
mice immunized with the glycan-peptide-TT with or without alum
or MPL, which indicated that the protective antibodies are likely
to be primarily of the IgM and IgG1 isotypes.
The glycopeptide-TT conjugate is immunogenic and
protective against disseminated candidiasis in outbred
mice
The efficacy of the b-(Man)3-Fba-TT conjugate vaccine against
disseminated candidiasis was also demonstrated in outbred mice.
Since a combination of MPL and alum may enhance the vaccine
response by rapidly triggering a local cytokine response leading to
an optimal activation of APCs [24], the tested Swiss Webster mice
were immunized with the b-(Man)3-Fba-TT conjugate alone or as
a mixture with both alum and MPL. Negative control mice were
Figure 4. b-Man)3-Fba-TT conjugate with or without adjuvant markedly induced high antibody titers and protection against
disseminated candidiasis in immunized mice as compared to controls. Mice immunized with b-(Man)3-Fba-TT prepared in either alum or
MPL, or without adjuvant developed robust antibody responses against both the Fba peptide (A) and the b-(Man)3 epitope (B). (C) Protective
immunity was induced by (b-Man)3-Fba-TT when either alum or MPL was used as the adjuvant. Protection was nearly as great even when adjuvant
was omitted as compared to DPBS or adjuvant only controls (P,0.01). (D) Immunized mice had reduced or non-detectable CFUs per kidney pairs
compared to control groups (P,0.001).
doi:10.1371/journal.pone.0035106.g004
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(Man)3-Fba-TT, with or without adjuvant, induced robust and
consistent antibody responses against both the b-(Man)3
(Figure 6A) and the Fba epitopes (Figure 6B) in immunized
outbred mice. Fourteen days following the last booster, immunized
mice were infected via the tail vein with a lethal dose of C. albicans
3153A, as we have described previously. Similar to our previous
findings in BALB/c mice, the outbred mice vaccinated with b-
(Man)3 –Fba-TT conjugate vaccine, when administered alone or
with alum and MPL, markedly improved the survival of infected
mice (Figure 6C). Consistently, the immunized mice had
significantly lower live fungal cells in their kidneys as compared
to negative controls (p,0.001) (Figure 6D).
Antibodies in immune sera bind yeast and hyphal forms
of C. albicans
Immune serum from animals immunized with the b-(Man)3-
Fba-TT conjugate contained antibodies specifically reactive with
the cell surface of yeast forms as demonstrated by flow cytometric
analyses. A fluorescence shift similar in magnitude to the control
antibody, MAb B6.1, was observed upon testing of the immune
serum (Figure 7A). This reactivity of immune serum was removed
by pre-absorption with C. albicans yeast forms (Figure 7B). The
binding pattern was similar with immune sera collected from mice
vaccinated with b-(Man)3-Fba-TT alone, or when mixed with
either alum or MPL (data not shown).
Microscopic observations after immunofluorescence staining
with anti-b-(Man)3-Fba-TT conjugate immune serum showed
reactivity with both yeast and filamentous forms of C. albicans
strain 3153A (Figure 7C), which was expected since we previously
showed that the vaccine glycan and peptide epitopes are surface
expressed [7,17,18]. The microscopic analysis confirmed the flow
cytometry results and extended the observations to include hyphal
forms of the fungus. The specific antibody reactivity was again
confirmed by the absence of fluorescence by immune serum pre-
absorbed with yeast forms of the fungus (Figure 7C). As with the
flow cytometry analyses, the positive reaction of immune serum
Figure 5. Passive transfer experiment was performed to confirm that antibody is responsible for the protection. (A) As immunized
mice, immune sera recipients had a prolonged survival time (P,0.01), confirming that induced antibodies were protective. (B) The serum from (b-
Man)3-Fba-TT immunized animals was capable of reducing the fungal load in the mouse kidneys compared with the infectious burden in mice were
given DPBS or pre-absorbed sera (P,0.001).
doi:10.1371/journal.pone.0035106.g005
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for the glycan epitope [25,26]. Moreover, essentially the same
pattern of C. albicans fluorescence was observed with immune
serum from mice vaccinated with b-(Man)3-Fba-TT alone, or
when mixed with alum/MPL. No reactivity with the fungus was
observed upon testing of serum from mice given adjuvant only or
pooled serum from untreated normal mice. In addition to these
findings, serum from mice immunized with the b-(Man)3-Fba-TT
conjugate reacted similarly with another C. albicans isolate (strain
SC5314) (data not shown).
Discussion
The discovery of numerous antigens on the fungal cell wall that
elicit protective antibody responses raises the possibility of
obtaining combined or even synergistic efficacious effects of
vaccines designed with multiple antigens, and/or passive therapies
that combine antibodies with different specificities [27,28]. The
novel fully synthetic b-(Man)3-Fba glycopeptide vaccine, which is
based on two C. albicans cell surface epitopes, induces impressive
protection against disseminated candidiasis in BALB/c mice [7].
Furthermore, in previous work we provided strong evidence that
antibodies specific for the glycan and peptide epitopes contribute
to the protection [17,29,30].
In the present study we extended our observations to include
C57BL/6 mice, which are more prone to Th1 responses and more
resistant to disseminated candidiasis as compared to the BALB/c
mice. By the same DC/CFA-based immunization protocols that
favored production of protective antibody, the b-(Man)3-Fba
conjugate induced a similar level of protection in C57BL/6 mice
as we found for BALB/c animals. Furthermore, protection was
observed regardless of the challenge strain of C. albicans. As with
the BALB/c mice, passive transfer of antibodies against the two
fungal epitopes to C57BL/6 naı ¨ve mice protected these animals
against disseminated candidiasis.
For the present and previous studies, the antigen-pulsed DC/
CFA immunization approach proved to be a powerful way of
overcoming the relatively weak immune response of the mouse to
Figure 6. The (b-Man)3-TT conjugate vaccine is immunogenic and protective against disseminated candidiasis in outbred mice.
Outbred CFWSwiss Webster (01S60) mice were immunized with the b-(Man)3-Fba-TT conjugate alone or mixed with adjuvants alum and MPL; control
mice were immunized with adjuvants (alum+MPL) only or DPBS buffer. Mice immunized with b-(Man)3-Fba-TT in either alum+MPL, or without
adjuvant induced robust antibody responses against both the b-(Man)3 epitope (A) and the Fba peptide (B). (C) Protective immunity was induced by
(b-Man)3-Fba-TT with or without adjuvant as noted by their prolonged survival time as compared to control mice that received DPBS or adjuvants
alone (P,0.01). (D) Immunized mice had reduced or non-detectable CFUs per kidney pairs compared to control groups.
doi:10.1371/journal.pone.0035106.g006
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vaccine. This immunization approach enabled us to arrive at the
defined vaccine composition [b-(Man)3-Fba] that provides a high
degree of protection against experimental hematogenously dis-
seminated candidiasis. The critical limitation of the immunization
approach is the use of DC and CFA, the former of which would
severely limit widespread vaccine use in humans and the latter of
which is unacceptable for human use. For those reasons we tested
the b-(Man)3-Fba along with alum and MPL as adjuvants in place
of DC and CFA. However, relatively weak anti-b-(Man)3 and
moderate anti-Fba responses were induced. Perhaps more
importantly, the new immunization approaches failed to induce
an IgM to IgG isotype shift, suggesting the lack of a memory cell
response. In addition, only the mice immunized with a
combination of the b-(Man)3-Fba conjugate and alum showed
evidence of protection, and even that group of animals was not
protected nearly as well as animals immunized by the DC/CFA
approach. The results did not improve by increasing the dose of
the b-(Man)3-Fba conjugate from 2.5 mgt o1 0mg, which led us to
investigate modifications of the vaccine itself.
In an attempt to increase the immunogenicity of the b-(Man)3-
Fba conjugate when using an acceptable immunization approach
for human use, we investigated the effects of coupling the
conjugate to tetanus toxoid (TT). The new glycopeptide vaccine
conjugate, b-(Man)3-Fba-TT, proved to be highly immunogenic as
it induced robust antibody responses when administered with
either alum or MPL as adjuvants. Moreover, prior to the second
booster dose, an isotype switch occurred from IgM to IgG
antibodies against for both the b-(Man)3 and Fba peptide epitopes.
This result indicated a possible memory cell response and,
perhaps, a vaccine that induces long-term immunity. Most
importantly, the (b-Man)3-Fba-TT conjugate administered with
either alum or MPL induced protection against disseminated
candidiasis on a par with the high level of protection observed with
the original DC/CFA immunization approach [7].
In previous work involving the DC/CFA immunization
approach, we found that the Fba peptide itself was immunogenic,
inducing not only a robust antibody response, but the response was
protective as well against disseminated candidiasis [8,17]. We were
surprised, therefore, to find that the Fba-TT conjugate in adjuvant
did not perform well in mice (Figure 3A & Table 3). We do not yet
Figure 7. Immune serum from (b-Man)3-Fba-TT vaccinated mice detected the presence of the vaccine epitopes on the surface of C.
albicans. (A) Antibodies in immune sera binding to the both epitopes expressed on the C. albicans cell surface were confirmed by flow cytometry.
The reactivity of immune serum (green) with live C. albicans cells to that of MAb B6.1 (blue line), which is specific for the C. albicans cell surface
epitope (b-Man)3,. Control serum (red line) was non-immune serum from mice that received adjuvant only. (B) Pre-absorbed MAb B6.1 (blue line) and
pre-absorbed immune sera (green line) were not reactive with fungal cell surface. (C) Confocal microscopic analyses confirmed that antibodies in
immune serum detect the vaccine epitopes on the surface of yeast forms, but are also reactive with the surface of hyphal forms of C. albicans. The
epitope display was similar to that due to fungal reactivity with MAb B6.1, which is specific for b-(Man)3 and was used as a positive
immunofluorescence control. As an additional negative control, immune serum pre-absorbed with C. albicans 3153A yeast cells did not react with
either yeast or hyphal forms of C. albicans.
doi:10.1371/journal.pone.0035106.g007
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immune interference caused by the acetylated modification at the
N-terminus (Figure 8) and, possibly, modifications may be
required of the tether between the small Fba moiety and the TT.
The large differences in vaccine efficacy between glycopeptide
conjugates b-(Man)3-Fba and b-(Man)3-Fba-TT when the same
adjuvant system was used led us to consider whether the tetanus
toxoid component was sufficient for inducing a protective immune
response. To test this hypothesis, b-(Man)3-Fba-TT administered
alone was compared to administration of the conjugate as either a
mixture made with alum or MPL. Mice that received the b-
(Man)3-Fba-TT conjugate prepared in either adjuvant responded
as expected by making robust antibody responses. Surprisingly,
mice that received the b-(Man)3-Fba-TT without any adjuvant
Figure 8. Scheme for synthesis of the conjugate vaccine. The glycoconjugate vaccine (GV) and the peptide vaccine lacking the mannotriose
component (PV) were synthesized from the advanced building blocks 1–3. The b-1,2 mannotriose derivatized with a triethylene glycol spacer 1; the
T-cell tetradecameric peptide (Fba) was assembled on a peptide synthesizer and a triethylene glycol tether was introduced at the C terminal end
followed by a single lysine residue which was derivatized on its side chain by a thioacetic acid residue, which gave the building blocks 2a or 2b.
Bromoacetate groups were introduced on approximately 20 of the lysine residues present in tetanus toxoid to give 3. GV was assembled by reacting
1 with 2a and then conjugating this product with 3. PV was prepared by conjugating 2b with 3. A detailed account of this synthesis will be reported
elsewhere (Cartmell et al. Carbohydr. Res submitted).
doi:10.1371/journal.pone.0035106.g008
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high level of protection against a lethal challenge with C. albicans as
evidenced by significantly increased survival times and reduced or
non-detectable kidney fungal burden at the time of sacrifice as
compared to control groups that received only adjuvants or DPBS
buffer prior to challenge. Furthermore, sera from mice immunized
against the b-(Man)3-Fba-TT conjugate transferred protection
against disseminated candidiasis to naı ¨ve mice, whereas C. albicans-
preabsorbed immune sera did not, which confirmed that induced
antibodies were protective. In conclusion, our results demonstrat-
ed that the addition of the TT to the vaccine conjugate provided
sufficient self-adjuvanting activity without the need for additional
adjuvant. This is the first report of which we are aware of a self-
adjuvanting glycopeptide vaccine against any infectious disease.
Prior to our work, immunostimulatory lipids conjugated to peptide
antigens resulted in self-adjuvanting (lipopeptide) vaccines now
tested in clinical trials [31,32]. The lipid parts of the lipopeptide
vaccines ranged from simple single fatty acid chains to complex
lipids and glycolipids. Several self-adjuvanting mRNA vaccines,
administered by an intradermal route, also induced anti-tumor
immune responses [33]. We show in our study, however, that the
coupling of a carrier protein component (TT) to the glycopeptide
vaccine resulted in a self-adjuvanting conjugate, which lays the
foundation for the novel concept of self-adjuvanting glycopeptide
vaccines.
Protein carriers can influence the specificity, function, avidity,
and idiotype of the antibody response to polysaccharide-protein
conjugate vaccines [34]. We compared antibody isotype distribu-
tion of responses to both b-(Man)3 and Fba peptide epitopes in
immune sera from mice vaccinated against b-(Man)3-Fba or b-
(Man)3-Fba-TT with different adjuvant systems. IgM specific for
both fungal epitopes was detected in sera of all immunized
animals. IgG1 against the two epitopes was produced in sera of
mice immunized with either b-(Man)3-Fba pulsed DC or b-
(Man)3-Fba-TT with or without adjuvant. Interestingly, conjuga-
tion of TT to b-(Man)3-Fba led to the appearance of IgG2a
specific for b-(Man)3 and Fba peptide epitopes. In contrast, the
antibody responses to b-(Man)3-Fba without adjuvant, or with
either alum or MPL as adjuvant consisted only of IgM antibodies.
IgG1 and IgG2a were the major IgG subclasses against both the
fungal glycan part and peptide parts of the b-(Man)3-Fba-TT
conjugate, but when MPL was used as adjuvant, the IgG2a and
IgG2b subclasses were detected with specificity for the b-(Man)3
epitope only. In the mouse, IgG2a and IgG3 efficiently fix
complement and promote opsonophagocytosis [35–38], and
IgG2a binds to the high-affinity macrophage Fcc receptor [39].
These considerations may well explain the higher level of
protection against candidiasis that was observed in mice
immunized against the b-(Man)3-Fba-TT with or without adjuvant
as compared to those that received the b-(Man)3-Fba formulation
with adjuvant. Although the mechanism of protection afforded by
antibodies specific for the Fba peptide part of the vaccine is under
investigation, the importance of complement fixation for protec-
tion provided by antibodies specific for the b-(Man)3 has been
established [18,19]. These results show that TT not only enhances
the immunogenicity of the glycopeptide vaccine, but also obviates
the use of adjuvants.
Antibodies induced by non-DC/CFA approaches are appar-
ently responsible for the protection against disseminated candidi-
asis. This was demonstrated by passive transfer of immune serum,
which conferred protection to naive animals. Moreover, such
protection was not conferred by normal serum from non-
immunized mice or by immune serum pre-absorbed by C. albicans
yeast forms. These results were not surprising since our previous
work showed that immune serum from mice immunized against
the fungal glycan [25,29], monoclonal antibodies specific for the
glycan [25,29,40], and monoclonal antibody specific for the Fba
peptide component [17] of the vaccine all conferred protection
when given to naı ¨ve animals.
The efficacy of the b-(Man)3-Fba-TT conjugate vaccine in
prolonging the survival of mice after a lethal challenge with C.
albicans was also demonstrated in outbred mice. The b-(Man)3-
Fba-TT conjugate vaccine was immunogenic in Swiss Webster
mice in the absence of an adjuvant, eliciting strong glycan- and
peptide-specific antibodies and induced protection against candi-
diasis. Vaccine-mediated protection in this outbred mouse model
was associated with a reduction in the levels of CFU in kidneys.
Taken together, we found no evidence that protection had an
MHC bias as evidenced by vaccine efficacy in BALB/c and
C57BL/6 mice, and the vaccine effectiveness in outbred mice
provides further support that this formulation may induce
protection in humans as well. We also expect that establishment
of active immunity when the host is immunologically normal will
then protect that host upon an immunocompromised event later.
This expectation is based on our findings that antibodies specific
for the glycan part of the b-(Man)3-Fba-TT vaccine enhanced
resistance to disseminated candidiasis of normal and neutropenic
mice [29,41]. This is an important fundamental question because
a prevalent risk factor for enhancement of susceptibility to
disseminated candidiasis in humans and mice is neutropenia.
Detection of specific antibodies induced by the b-(Man)3-Fba-
TT vaccine were determined by ELISA in which wells of the plate
were coated with either b-(Man)3 conjugated to bovine serum
albumin or Fba peptide as a MAP conjugate to detect anti-glycan
and peptide antibodies, respectively. We also confirmed the
specificity of the response to both the glycan and peptide epitopes
by inhibition ELISA, in which free soluble b-(Man)3 or Fba
peptide inhibited the binding of antibodies in immune sera in a
dose-dependent manner (data not shown). The binding of the
specific antibodies to the actual fungal cell surface was confirmed
by flow cytometric analyses, which demonstrated binding to C.
albicans yeast forms, and by indirect immunofluorescence micros-
copy showing antibody reactivity with yeast and hyphal forms,
which is consistent with our reported observations on monoclonal
antibodies specific for the two fungal epitopes [17,25].
In other work, conjugates made of the synthetic glycan
covalently linked to tetanus toxoid was immunogenic in rabbits
[42,43], but was poorly immunogenic in mice [43]. In the present
work, the conjugate became highly immunogenic upon inclusion
of the Fba peptide [b-(Man)3-Fba-TT]. Since the Fba peptide
alone induces protection [7,17], its’ inclusion in the vaccine
construct not only increases immunogenicity, but also provides the
host with a dual immune recognition formulation to ensure
protection even against C. albicans mutants that may have lost the
ability to express one of the two vaccine epitopes. Additional
rationale for keeping the glycan as part of the vaccine is that,
although the Fba peptide is unique to C. albicans, responses against
the b-(Man)3 would be expected to protect against infection with a
variety of other clinically important Candida species [15], including
C. tropicalis [29,44], C. lusitaniae [45], C. guilliermondii [46,47] and
the majority of C. glabrata strains [48,49].
In summary, the development of an effective vaccine against
disseminated candidiasis represents an alternative to the often
ineffective antifungal drug therapeutic approach to management
of this disease. The findings in the present study indicate that the
b-(Man)3-Fba-TT glycopeptide vaccine is a promising candidate
for disease prevention. In a recent study, we obtained evidence
that antibody responses to at least the Fba component of the
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gastrointestinal tract colonization with the fungus and are
producing serum antibodies in response to the colonization [16].
This modified mouse model more closely simulates the situation in
most humans, thus providing additional confidence for going
forward with our vaccine approach in humans.
Materials and Methods
Candida albicans strains
C. albicans 3153A and SC5314 were grown as stationary-phase
yeast cells in glucose-yeast extract-peptone broth at 37uC, washed
and suspended to the appropriate cell concentration (5610
6/ml) in
Dulbecco’s PBS (DPBS; Sigma), and used to infect mice
intravenously (i.v.) as described [29,40]. C. albicans strain 3153A
was used also for serum antibody absorption, immunofluorescence
staining and flow cytometric analysis.
Mouse strains
Inbred strains BALB/c and C57BL/6, and outbred Swiss
Webster (ND4) female mice (NCI Animal Production Program or
Harlan) 5 to 7 weeks old were used. Mice were maintained and
handled in accordance with a protocol (#150) approved by the
Institutional Animal Care & Use committee (IACUC) regulations
at Children’s Hospital Research Institute in New Orleans.
Synthesis of the Conjugate Vaccine
The glycoconjugate vaccine (GV) and the control vaccine
lacking the mannotriose component (CV) were synthesized from
the advanced building blocks 1–3 (Figure 8). The b-1,2
mannotriose derivatized with a triethylene glycol spacer 1 was
synthesized as previously described [50]. The T-cell tetradeca-
meric peptide (Fba) was assembled on a peptide synthesizer and a
triethylene glycol tether was introduced at the C terminal end
followed by a single lysine residue which was derivatized on its side
chain by a thioacetic acid residue. This gave the building blocks 2a
or 2b. Bromoacetate groups were introduced on approximately 20
of the lysine residues present in tetanus toxoid (State Serum
Institute, Cophenhagen) to give 3. GV was assembled by reacting
1 with 2a and then conjugating this product with 3. CV was
prepared by conjugating 2b with 3. A detailed account of this
synthesis will be reported elsewhere (Cartmell et al. Carbohydr.
Res submitted).
Immunizations of mice
Conjugates b-(Man)3-Fba or b-(Man)3-Fba-TT were adminis-
tered at a subcutaneous (s.c.) location in the nape of the neck. The
conjugates were given alone or as a mixture made either with alum
(aluminum hydroxide gel, Sigma) or MPL (Lipid A, monopho-
sphoryl, Sigma) or as a combination of both adjuvants. Negative
control groups of mice were given DPBS buffer or adjuvant only.
Immunization doses and schedules were 100 ml of 2.5 mgo r1 0mg
of either conjugate alone, or as a mixture containing either
conjugate along with 50 mg alum or 10 mg MPL on days 1, 21 and
62. In some experiments the two adjuvants were combined and
mixed with antigen for the priming and booster doses. Serum
samples were collected 14 days after each immunization and tested
by ELISA.
Serological assays
Immune sera were analyzed for antibody titers after each
immunization as described below. Although the titers increased
after each dosing, the most profound changes were usually
observed after the first booster, which is the result we chose to
show for comparison of vaccine responses between the various
groups.
For DC/CFA-based immunizations, DCs were pulsed in vitro
with b-(Man)3-Fba vaccine as described [7]. The mice were given
a priming dose and boosted at day 14 with fresh antigen-pulsed
DCs and boosted a second time at day 28 with antigen (2.5 mg)
emulsified in complete Freund adjuvant (CFA) given subcutane-
ously (s.c.). Control groups consisted of mice given DPBS, DC, or
DC+CFA alone at the time of priming and boosters. For b-
(Man)3-Fba, Fba-TT or (b-(Man)3-Fba-TTadministered alone or
with alum or MPL, control groups were given adjuvant alone or
DPBS buffer. Serum samples were collected 14 days after each
immunization, diluted 1:100 and tested by ELISA on plates coated
with cell wall mannan extract from C. albicans, or Fba-MAP
peptide (GenScript) or b-(Man)3-BSA as previously described
[7,16]. Briefly, C. albicans mannan extract [51], which is composed
mainly of mannan, or synthetic b-(Man)3 coupled to BSA was
dissolved at 4 mg/ml in carbonate buffer (pH 9.6); Fba-MAP
(GenScript) was dissolved at 10 mg/ml in carbonate coating buffer
(pH 9.5). Each was used to coat 96-well ELISA plates for testing
duplicate 1:100 dilutions of samples of each immune serum and
control sera. Color development for each well was achieved by
secondary antibody, goat anti-mouse polyvalent immunoglobulin
(IgG, IgA, IgM) peroxidase conjugated antibody (diluted 1:10,000
in PBST) (Sigma) and substrate (O-phenylenediamine and H2O2);
OD reading was determined at 492 nm.
To determine dilution endpoint ELISA titers, serial 2-fold
dilutions of sera in blocking buffer were prepared. The endpoint
ELISA titer was taken as the reciprocal of the last serum dilution
with an OD reading at least two-fold greater than the mean OD of
negative control samples plus twice the standard deviation.
For antibody isotype and subclass determinations, peroxidase-
conjugated rabbit anti-mouse heavy chain specific IgM, IgG1,
IgG2a, IgG2b, and IgG3 (Rockland, PA) were diluted 1:10,000 in
blocking buffer and added to the appropriate wells, followed by
addition of O-phenylenediamine substrate and H2O2 for color
development and absorbance as before.
Fungal challenge and assessment of protection
Two weeks after the second boost, immune and control mice
were infected i.v. with a lethal dose of live C. albicans yeast cells
(5610
5 in 0.1 ml of DPBS) prepared as described above and as
before [7]. Passively immunized mice (below) also received the
same challenge dose. Protection was evaluated by monitoring
animal survival for 50–120 days, depending on the experiment.
The mice were monitored for development of a moribund state,
defined as being listless, disinterested in food or water, and
nonreactive to finger probing. At the time that a mouse was
deemed moribund, it was sacrificed and their kidneys were
homogenized in DPBS and plated onto a nutrient agar to
determine colony forming units (CFUs). After 50–120 days, the
experiments were terminated and all the survivors at that time
were sacrificed and their kidneys were assessed for CFU as before.
The lowest limit of detection for the CFU assay was 50 CFU per
kidney pair.
Passive transfer of immune sera
Immune sera were obtained from vaccinated mice, pooled and
stored at 220uC or absorbed before freezing with C. albicans
3153A yeast cells as before [7,17,29]. Immune sera pre-absorbed
with yeast or DBPS buffer were used as passive transfer negative
controls. Pre-absorbed immune sera were tested and found
negative for antibodies against both b-(Man)3 and Fba peptide
by ELISA as described above. Naı ¨ve BALB/c mice received
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serum or control serum or DBPS buffer. Four hours later, all mice
were challenged i.v. with C. albicans (5610
5 yeast cells). All animals
received a second dose (200 ml) of serum or negative control
material i.p. 24 h after the first dose. Infected mice were sacrificed
when they became moribund and their kidneys were assessed for
CFUs as above.
Flow cytometric analysis and immunofluorescence
microscopy
Distribution of the b-(Man)3 and Fba peptide epitopes on yeast
cells was determined by use of immune serum for flow cytometric
analysis and indirect immunofluorescence. One hundred micro-
liters of immune serum (1:100 dilution in 1% BSA/DPBS) was
added to a pellet of C. albicans yeast cells (5610
6) that was
prewashed with DPBS buffer three times. The yeast cells were
suspended in the immune serum [from b-(Man)3-Fba-TT
immunized mice] preparation and incubated while shaking by
rotation at room temperature (RT, 22–24uC) for 1–2 h. After
incubation, the yeast cells were washed with DPBS three times,
suspended in 200 ml of fluorescein- labeled goat anti-mouse IgM
(u-chain specific; Sigma) (stock solution, 1 mg/ml; working
solution, 20 mg/ml of DPBS) and incubated at RT described
above for 0.5 h. The yeast cells were washed with DPBS three
times and suspended in 500 ml of DPBS. Flow cytometry was
performed using a BD Biosciences FACSVantage SE equipped
with an argon laser excitation at 488 nm. 10,000 cells in each
sample were analyzed (CellQuest Pro software)
For immunofluorescence assays, the fungal cells were immuno-
stained and washed as described above and suspended in the
200 ml DPBS buffer. The cells were observed by confocal
microscopy (LSM 510, Zeiss). The distribution of the b-(Man)3
and Fba peptide epitopes on the yeast cell surface was compared to
that obtained with yeast cells fluorescently stained for detection of
the MAb B6.1 epitope. Negative controls included showing non-
reactivity of an irrelevant isotype control IgM MAb S-9 [52] (data
not shown) and use of fluorescein-labeled goat anti-mouse
secondary antibody only. As an additional control, pre-absorbed
immune serum prepared as described above was tested for the
binding reactivity to the C. albicans cell surface.
Statistical analysis
Data were analyzed by GraphPad Prism 4 software (GraphPad
Inc.). ELISA data were assessed for statistical significance by curve
fit analysis. Differences in median survival time and in survival
rates in C. albicans–challenged mice were analyzed by nonpara-
metric two-tailed Mann-Whitney U test or Fisher’s exact test,
respectively. Differences in survival curves were assessed by the
log-rank test. Data from CFU counts, in both in vitro and in vivo
experiments, were analyzed by two-tailed Student’s t test. Multiple
comparisons were made by analysis of variance (one-way
ANOVA) followed by Newman-Keuls post-test.
Supporting Information
Figure S1 b-(Man)3-Fba pulsed DC/CFA vaccine in-
duced protective responses in C57BL/6 mice against
disseminated candidiasis. (A) Vaccination with b-(Man)3-Fba
by the DC/CFA-based approach induced protection against
disseminated candidiasis by C. albicans strain 3153A in C57BL/6
mice. Vaccinated mice had a prolonged survival time as compared
to control mice that received DCs+CFA, DCs alone or DPBS
(P,0.001). (B) Immunized mice also had greatly reduced or non-
detectable CFU in their kidneys as compared to control mice
(P,0.01). (C) Pooled serum from immune mice transferred
protection to naı ¨ve mice. Note that the immunized mice had a
similar survival curve as the naı ¨ve mice that received the immune
serum. (D) Immunized mice and mice that received antiserum had
significantly fewer or non-detectable CFU in kidneys as compared
to the control groups that received either the immune serum that
was preabsorbed with C. albicans yeast cells, or DPBS buffer
(P,0.001). (E) Vaccination induced significant protection regard-
less of the fungal strain. Similar protection patterns were obtained
when immunized mice were challenged with C. albicans strains
SC5314 and 3153A.
(TIF)
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